title: Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease.
abstract: Regulatory T cells (Treg) play a key role in maintaining the balance of immune responses in human health and in disease. Treg come in many flavors and can utilize a variety of mechanisms to modulate immune responses. In cancer, inducible (i) or adaptive Treg expand, accumulate in tissues and peripheral blood of patients, and represent a functionally prominent component of CD4+ T lymphocytes. Phenotypically and functionally, iTreg are distinct from natural (n) Treg. A subset of iTreg expressing ectonucleotidases CD39 and CD73 is able to hydrolyze ATP to 5'-AMP and adenosine (ADO) and thus mediate suppression of those immune cells which express ADO receptors. iTreg can also produce prostaglandin E2 (PGE2). The mechanisms responsible for iTreg-mediated suppression involve binding of ADO and PGE2 produced by iTreg to their respective receptors expressed on T effector cells (Teff), leading to the up-regulation of adenylate cyclase and cAMP activities in Teff and to their functional inhibition. The potential for regulating these mechanisms by the use of pharmacologic inhibitors to relieve iTreg-mediated suppression in cancer suggests the development of therapeutic strategies targeting the ADO and PGE2 pathways.
authors.affiliation: Department of Pathology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.
authors.forename: Theresa L
authors.initials: TL
authors.lastname: Whiteside
authors.forename: Edwin K
authors.initials: EK
authors.lastname: Jackson
keywords: cancer inducible regulatory T cells; natural regulatory T cells; tumor microenvironment
references.citation: J Exp Med. 2007 Jun 11;204(6):1257-65
references.pmid: 17502665
references.citation: Cancer Immunol Immunother. 2008 Nov;57(11):1611-23
references.pmid: 18327580
references.citation: Annu Rev Med. 2013;64:131-44
references.pmid: 23020877
references.citation: Nat Rev Cancer. 2005 Apr;5(4):263-74
references.pmid: 15776005
references.citation: Adv Cancer Res. 2010;107:57-117
references.pmid: 20399961
references.citation: Expert Opin Biol Ther. 2010 Jul;10(7):1019-35
references.pmid: 20415597
references.citation: Nat Med. 2004 Sep;10(9):942-9
references.pmid: 15322536
references.citation: Blood. 2008 Aug 1;112(3):610-8
references.pmid: 18519811
references.citation: Int J Cancer. 2010 Aug 15;127(4):759-67
references.pmid: 20518016
references.citation: Eur J Immunol. 2007 Jun;37(6):1575-83
references.pmid: 17474155
references.citation: Nat Immunol. 2003 Dec;4(12):1206-12
references.pmid: 14578884
references.citation: Nat Rev Drug Discov. 2008 Sep;7(9):759-70
references.pmid: 18758473
references.citation: J Immunol. 2010 Jul 1;185(1):335-44
references.pmid: 20505140
references.citation: Int J Oncol. 2008 Mar;32(3):527-35
references.pmid: 18292929
references.citation: Nat Rev Immunol. 2008 Jul;8(7):523-32
references.pmid: 18566595
references.citation: Immunity. 2012 Feb 24;36(2):161-3
references.pmid: 22365661
references.citation: Sci Transl Med. 2012 Dec 12;4(164):164ra159
references.pmid: 23241743
references.citation: Immunology. 2008 May;124(1):13-22
references.pmid: 18346152
references.citation: Cancer Immunol Immunother. 2007 Sep;56(9):1429-42
references.pmid: 17265021
references.citation: Front Biosci (Schol Ed). 2010 Jun 01;2:980-92
references.pmid: 20515837
references.citation: Blood. 2007 Aug 15;110(4):1225-32
references.pmid: 17449799
references.citation: Clin Cancer Res. 2007 Nov 1;13(21):6301-11
references.pmid: 17975141
references.citation: PLoS Pathog. 2013;9(4):e1003319
references.pmid: 23658513
references.citation: Immunity. 2005 May;22(5):633-42
references.pmid: 15894280
references.citation: Sci Transl Med. 2011 May 18;3(83):83ra40
references.pmid: 21593400
references.citation: J Clin Oncol. 2006 Dec 1;24(34):5373-80
references.pmid: 17135638
references.citation: PLoS One. 2008 Sep 08;3(9):e3161
references.pmid: 18776930
references.citation: Blood. 2005 Apr 1;105(7):2877-86
references.pmid: 15613550
references.citation: Immunity. 2009 May;30(5):626-35
references.pmid: 19464985
references.citation: Oncogene. 2010 Sep 30;29(39):5346-58
references.pmid: 20661219
references.citation: Endocr Metab Immune Disord Drug Targets. 2006 Sep;6(3):239-47
references.pmid: 17017975
references.citation: Cancer Immunol Immunother. 2011 Jan;60(1):111-22
references.pmid: 20960188
references.citation: Nat Rev Immunol. 2011 Feb;11(2):119-30
references.pmid: 21267013
references.citation: Cancer Res. 2009 Jul 1;69(13):5490-7
references.pmid: 19570783
references.citation: Clin Cancer Res. 2008 Oct 15;14(20):6674-82
references.pmid: 18927310
references.citation: Oncogene. 2008 Oct 6;27(45):5904-12
references.pmid: 18836471
references.citation: Nat Rev Immunol. 2010 Jul;10(7):490-500
references.pmid: 20559327
references.citation: Eur J Immunol. 2007 Jan;37(1):129-38
references.pmid: 17154262
references.citation: Biochem Soc Trans. 2013 Feb 1;41(1):245-51
references.pmid: 23356291
references.citation: J Immunol. 2012 Feb 1;188(3):976-80
references.pmid: 22198953
references.citation: Drug Discov Today. 2009 Oct;14(19-20):982-91
references.pmid: 19638320
references.citation: Clin Immunol. 2011 Sep;140(3):218-22
references.pmid: 21570917
references.citation: J Immunol. 2006 Jun 1;176(11):6752-61
references.pmid: 16709834
references.citation: J Biol Chem. 2010 Mar 5;285(10):7176-86
references.pmid: 19858205
references.citation: J Exp Med. 1996 Aug 1;184(2):387-96
references.pmid: 8760792
references.citation: Cancer Res. 2011 Feb 15;71(4):1263-71
references.pmid: 21303976
references.citation: Cancer Res. 2007 Sep 15;67(18):8865-73
references.pmid: 17875728
references.citation: Nat Immunol. 2002 Feb;3(2):135-42
references.pmid: 11812990
references.citation: J Biol Chem. 2012 Feb 17;287(8):5301-9
references.pmid: 22215671
references.citation: Br J Cancer. 2012 Mar 27;106(7):1306-13
references.pmid: 22415233
references.citation: J Immunol Methods. 2009 Jul 31;346(1-2):55-63
references.pmid: 19450601
references.citation: J Transl Med. 2008 Apr 22;6:19
references.pmid: 18430198
references.citation: Purinergic Signal. 2006 Jun;2(2):343-50
references.pmid: 18404474
references.citation: Eur J Immunol. 2008 Apr;38(4):925-7
references.pmid: 18395862
references.citation: J Immunol Methods. 2011 Jun 30;369(1-2):59-68
references.pmid: 21513715
references.citation: Clin Cancer Res. 2012 Jun 1;18(11):3022-9
references.pmid: 22510350
references.citation: Cancer Immunol Immunother. 2007 May;56(5):641-8
references.pmid: 16960692
references.citation: Breast Cancer Res. 2011 Apr 26;13(2):R47
references.pmid: 21521526
references.citation: J Exp Med. 2003 Dec 15;198(12):1875-86
references.pmid: 14676299
references.citation: Cancer Res. 2011 Sep 1;71(17):5601-5
references.pmid: 21846822
references.citation: J Biol Chem. 2010 Sep 3;285(36):27571-80
references.pmid: 20558731
references.citation: Curr Opin Immunol. 2011 Oct;23(5):641-7
references.pmid: 21840184
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3706-15
references.pmid: 18559587
references.citation: Blood. 2012 May 10;119(19):4430-40
references.pmid: 22438251
references.citation: Blood. 2013 Jul 4;122(1):9-18
references.pmid: 23678003
references.citation: Immunol Rev. 2001 Aug;182:68-79
references.pmid: 11722624
references.citation: Recent Pat Anticancer Drug Discov. 2008 Jan;3(1):55-62
references.pmid: 18289124
references.citation: Blood. 2009 Jul 16;114(3):555-63
references.pmid: 19465693